Clinical Trial Update: Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Dimolegin 60 mg once daily to Enoxaparin for prevention of venous thromboembolism in patients undergoing total hip or knee replacement h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Dimolegin (dimolegin)
• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Avexima Diol LLC | Conditions: Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee | Phase 3 | Status: COMPLETED